ArticleAntimicrobial agents and chemotherapy2008
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024Review
- Strategies to Improve the Potency of Oxazolidinones towards Bacterial Biofilms.Chemistry, an Asian journal · 2022Review
- Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics.Nature structural & molecular biology · 2022Article
- Clinical Utility of Lefamulin: If Not Now, When?Current infectious disease reports · 2020Review
- Comprehensive spectral identification of key intermediates to the final product of the chiral pool synthesis of radezolid.Chemistry Central journal · 2017Article
- New Horizons in Mycoplasma genitalium Treatment.The Journal of infectious diseases · 2017Review
- Antibiotics in the clinical pipeline at the end of 2015.The Journal of antibiotics · 2017Review
- Article
- Targeting Antibiotic Resistance.Angewandte Chemie (International ed. in English) · 2016Review
- Investigational drugs to treat methicillin-resistant Staphylococcus aureus.Expert opinion on investigational drugs · 2016Review
- Complex long-distance effects of mutations that confer linezolid resistance in the large ribosomal subunit.Nucleic acids research · 2015Article
- Development of novel antibacterial drugs to combat multiple resistant organisms.Langenbeck's archives of surgery · 2015Review
- An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants.Bioorganic & medicinal chemistry · 2014Article
- Antibiotics and bacterial resistance in the 21st century.Perspectives in medicinal chemistry · 2014Review
- Investigational antimicrobial agents of 2013.Clinical microbiology reviews · 2013Review
- Advances in MRSA drug discovery: where are we and where do we need to be?Expert opinion on drug discovery · 2013Review
- New antibiotics for bad bugs: where are we?Annals of clinical microbiology and antimicrobials · 2013Review
- Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.Antimicrobial agents and chemotherapy · 2010Article
- Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.Antimicrobial agents and chemotherapy · 2010Article
- Linezolid Resistance in Staphylococci.Pharmaceuticals (Basel, Switzerland) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rx-01_423 and Rx-01_667 are two members of the family of oxazolidinones that were designed using a combination of computational and medicinal chemistry and conventional biological techniques. The compounds have a two- to eightfold-improved potency over linezolid against serious gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci. This enhanced potency extends to the coverage of linezolid-resistant gram-positive microbes, especially multidrug-resistant enterococci and pneumococci. Compounds from this series expand the spectrum compared with linezolid to include fastidious gram-negative organisms like Haemophilus influenzae and Moraxella catarrhalis. Like linezolid, the Rx-01 compounds are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.